Cheskin L J, Miday R, Zorich N, Filloon T
Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Md 21224, USA.
JAMA. 1998 Jan 14;279(2):150-2. doi: 10.1001/jama.279.2.150.
Olestra, a nonabsorbable, energy-free fat substitute used in snack foods, has been anecdotally reported to cause gastrointestinal (GI) adverse events, although such effects were not expected based on results from randomized trials, in which it was consumed in typical snack patterns.
To determine whether ad libitum consumption of potato chips made with the fat substitute olestra results in a different level of GI symptoms than regular chips made with triglyceride (TG).
Randomized, double-blind, parallel, placebo-controlled trial.
A suburban Chicago, III, multiplex cinema.
A total of 1123 volunteers aged 13 to 88 years.
Subjects were given a beverage and an unlabeled, white 369-g (13-oz) bag of potato chips made with olestra or TG during a free movie screening.
Total and specific GI symptoms reported during a telephone interview conducted from 40 hours to 10 days after ingestion; level of potato chip consumption; and satiety level.
Of 563 evaluable subjects in the olestra chip group, 89 (15.8%) reported 1 or more GI symptoms, while 93 (17.6%) of the 529 evaluable subjects in the regular TG chip group did so (difference in symptom frequency between olestra and TG, -1.8; 95% confidence interval, -6.2 to 2.7; P=.47). For specific GI symptoms (eg, gas, diarrhea, abdominal cramping), there were no significant differences between olestra and TG chips. Fewer olestra chips were consumed than TG chips (60 vs 77 g [2.1 vs 2.7 oz]; P<.001), with olestra chips receiving lower taste scores (5.6 vs 6.4 on a 9-point scale; P<.001). Consumption levels did not correlate with the rate of symptom reporting in either the olestra or TG group. There was no difference in satiety scores between olestra and TG chips (5.7 vs 5.9 on a 9-point scale; P=.07).
This study demonstrates that ad libitum consumption of olestra potato chips during 1 sitting is not associated with increased incidence or severity of GI symptoms, nor does the amount consumed predict who will report GI effects after short-term consumption of either olestra or TG potato chips.
奥利司他是一种用于休闲食品的不可吸收、不含能量的脂肪替代品，有传闻称其会导致胃肠道（GI）不良事件，尽管根据随机试验结果预计不会出现此类影响，在这些试验中，它是以典型的休闲食品模式食用的。
确定随意食用用脂肪替代品奥利司他制成的薯片是否会导致与用甘油三酯（TG）制成的普通薯片不同程度的胃肠道症状。
随机、双盲、平行、安慰剂对照试验。
伊利诺伊州芝加哥郊区的一家多厅电影院。
总共1123名年龄在13至88岁之间的志愿者。
在免费电影放映期间，给受试者提供一种饮料和一袋未标明标签的、白色的369克（13盎司）用奥利司他或TG制成的薯片。
在摄入后40小时至10天进行的电话访谈中报告的总体和特定胃肠道症状；薯片的食用量；以及饱腹感水平。
在奥利司他薯片组的563名可评估受试者中，89人（15.8%）报告了1种或更多胃肠道症状，而在普通TG薯片组的529名可评估受试者中，有93人（17.6%）报告了此类症状（奥利司他和TG之间的症状频率差异为-1.8；95%置信区间为-6.2至2.7；P = 0.47）。对于特定的胃肠道症状（如腹胀、腹泻、腹部绞痛），奥利司他薯片和TG薯片之间没有显著差异。食用的奥利司他薯片比TG薯片少（60克对77克[2.1盎司对2.7盎司]；P<0.001），奥利司他薯片的口味评分较低（在9分制中为5.6分对6.4分；P<0.001）。食用量与奥利司他组或TG组的症状报告率均无相关性。奥利司他薯片和TG薯片的饱腹感评分没有差异（在9分制中为5.7分对5.9分；P = 0.07）。
本研究表明，一次随意食用奥利司他薯片与胃肠道症状的发生率或严重程度增加无关，食用量也无法预测在短期食用奥利司他或TG薯片后谁会报告胃肠道影响。
